A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Ibrutinib (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Folinic acid; Mesna; Methotrexate; Vincristine
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2016 Planned number of patients changed from 50 to 100.
- 13 Dec 2016 Status changed from active, no longer recruiting to recruiting.
- 06 Dec 2016 Preliminary results (n=50, as of 2 Aug 2016), presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.